A Case Report and Review of Literature: Epithelioid Hemangioendothelioma—An Uncommon Challenging Case

Sweta Soni1 Bharti Devnani2 Poonam Elhence3 Kapil Soni4 Deepak Vedant3 Palak Gupta4 Puneet Pareek2 Rakesh Kumar Vyas2

1 Department of Radiation Oncology, All India Institute of Medical Sciences, Rajkot, Rajkot, Gujarat, India
2 Department of Radiation Oncology, All India Institute of Medical Sciences, Jodhpur, Jodhpur, Rajasthan, India
3 Department of Pathology, All India Institute of Medical Sciences, Jodhpur, Jodhpur, Rajasthan, India
4 Department of ENT, All India Institute of Medical Sciences, Jodhpur, Jodhpur, Rajasthan, India

Address for correspondence Bharti Devnani, MBBS, DNB, Department of Radiation Oncology, All India Institute of Medical Sciences, Basni, Jodhpur 342005, Rajasthan, India (e-mail: bhartidevnani@gmail.com).

Abstract

Introduction  Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor of soft tissue and bone that may uncommonly occur in the liver, lung, and head and neck region. EHEs have a higher predilection for recurrence at the local site as well as distant metastasis. Surgical excision is important and is the treatment in localized diseases. A decision to give adjuvant radiotherapy should be subjective and may differ on case-to-case basis. Limited studies are available exploring the role of targeted or systemic therapy.

Case Presentation  A 56-year-old lady represented with right-sided submandibular region EHE with bilateral lung metastasis. The patient underwent surgery and radiotherapy followed by targeted therapy tab pazopanib for systemic control. At 2 years of follow-up, positron emission tomography-computed tomography showed local regional control and stable systemic diseases.

Conclusion  The uncertainty in choosing the most suitable treatment of EHE patients is high and may result in dissatisfactory outcomes among several patients. The present case study identified a treatment dilemma making management more challenging for rare EHE with mandibular involvement.

Keywords
► hemangioendothelioma
► surgery
► radiotherapy
► pazopanib
► outcomes
► case report

Introduction

Sarcomas are malignant tumors of the skeletal and extraskeletal connective tissue that can arise from mesenchymal tissue at any body site. Uncommon subtypes of sarcoma together account for 5% of sarcoma tumors.1 They are especially challenging to diagnose and treat. Epithelioid hemangioendothelioma (EHE) is an uncommon vascular sarcoma that accounts for less than 1% of all vascular tumors.2 The World Health Organization describes malignant EHE as an intermediate malignant neoplasm.2 The risk of recurrence at the local site and failures distantly are high with EHEs; however, tumor-specific mortality rates may rely on their anatomic site of origin. There are only limited cases reported of EHE in the face–neck region, with an appearance

ISSN 0971-5851.

© 2023. The Author(s).
This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
in the oral cavity being extremely rare.³ The frequently reported oral cavity site for EHE is the tongue, which accounts for 26% of cases. This is followed by the mandibular and maxillary gingiva involvement, contributing to 22 and 19% of cases, respectively.⁴,⁵ The present study describes a rare case of mandibular EHE, its management, and a summary of the literature available.

**Case Presentation**

A 56-year-old lady, with no comorbidities and no habits presented with right submandibular swelling which gradually increased over 2 years. On clinical examination, the submandibular mass was lobulated and soft in consistency measuring 3 × 4 cm and not fixed to the overlying skin. There were no signs of inflammation and the swelling was not tender to touch. There was a palpable left level Ib neck node of 1.5 × 2 cm in size in the contralateral neck. The rest of the head and neck area examination was noncontributory. Computed tomography (CT) imaging (Fig. 1A) done was suggestive of a 28 × 27 × 39 mm sized ill-defined soft tissue lesion seen in the hemimandible along the right lower alveolus which was causing destructive cortical erosion. The adjacent enhancing soft tissue component showed loss of fat planes with the right submandibular gland inferiorly. A 1.7 × 2.2 cm sized FDG avid left cervical level Ib lymph node was also noted. Heterogeneously, FDG avid discrete cervical level Ia and bilateral level II lymph nodes were also present. Mild FDG avid multiple subpleural and parenchymal nodules were noted in bilateral lung fields suggestive of metastasis (Fig. 1C). Biopsy from the right submandibular region was suggestive of EHE. In view of rare disease and asymptomatic suspicious lung metastasis, the case was discussed in a multidisciplinary tumor board following which the patient was taken up for wide local excision with right segmental mandibullectomy with bilateral supramohyoid neck dissection. Histopathology of the resected specimen was suggestive of EHE involving the right submandibular gland and underlying bone (Fig. 2A) with maximum tumor size of 2.8 cm, medial and lateral soft tissue margins were involved by the tumor, perineural invasion was present (Fig. 2B), and lymphovascular invasion was not seen. Federation Nationale des Centres de Lutte Contre Le Cancer (FNCLCC) grade 4, mitotic rate was < 1/50 high-power field (HPF), and necrosis 10% (Fig. 2C). One lymph node in the left level Ib was positive (out of 5), while the right-sided nodes were negative. Tumor cells were immuno reactive for CD34 (Fig. 2D). In view of positive margin and lymph node involvement, the patient was planned for adjuvant radiation to a dose of 60 Gy in 30 fractions to postoperative bed and involved the lymph node region by image-guided external beam radiotherapy (RT) technique. In phase 1, 50 Gy in 25 fractions was delivered to the tumor bed and bilateral neck region, and in phase 2 (boost), 10 Gy in 5 fractions was delivered to the tumor bed and involved the nodal region. Therefore, a total of 60 Gy in 30 fractions, 2 Gy per fraction, one fraction daily, over 6 weeks along with cisplatin chemotherapy (40 mg/m²) concurrently was given once a week, which she tolerated well with grade 1 dermatitis and grade 2 mucositis. The patient recovered from acute toxicities 2 weeks after completion of RT and was started on targeted therapy tablet pazopanib (dose 400 mg) twice a day to control systemic disease and reduce the risk of locoregional failure. PET-CT scan repeated after 3 months was suggestive of postoperative fibrosis of the right submandibular region with stable pulmonary metastasis. At 2-year follow-up, the patient is asymptomatic and on tablet pazopanib dose reduced to 200 mg twice a day due to oral mucositis. Latest PET-CT showed local-regional control and metabolically inactive pulmonary metastatic diseases.

**Discussion**

Hemangioendothelioma (HE) is a rare vascular neoplasm with an equivocal biological behavior, intermediate between highly malignant angiosarcoma and completely benign hemangioma. HE involving the skin and soft tissue includes papillary, retiform, kaposiform, epithelioid, pseudomyogenic, and composite type.⁶ EHE is distinguished by epithelioid or histiocytoid cells with endothelial features, accounting for less than 1% of all vascular tumors. In 1975, HE was reported initially by Dail and Liebow as pulmonary in origin.⁷ Earlier, it was described as an bronchoalveolar cell carcinoma with vascular invasion with an aggressive behavior, hence, the name given was an intravascular bronchioloalveolar tumour.⁸,⁹ In 1982, the name EHE was coined by Weiss and Enzinger to define a vascular tumor of soft tissue and bone with characteristic features intermediate between hemangiomia and angiosarcoma.¹⁰,¹¹

EHE has been considered to be the most aggressive among all types of HEs with a high risk of distant metastasis and mortality, accounting for 20 to 30% and 10 to 20% cases, respectively.¹² One of the largest series of EHE reported, recurrences at local site in 13% of cases and regional-distant failure in approximately 31% sites such as regional lymph nodes, lungs, liver, and bone. The authors concluded in a study with 49 patients of soft tissue EHE, that the risk of metastasis was greater in lesions > 3 cm and those showing ≥ 3 mitotic figures per 50 HPF.¹³ The etiology of EHE up to this time is unclear. At the molecular front, various angiogenic stimulators may act as promoters of endothelial cell proliferation.¹⁴ A study suggests that for proliferation of EHE, monocyte chemoattractant protein-1 is needed and by stimulation the angiogenic nature of endothelial cell, it might promote lesions to proliferate.¹⁵ EHE is diagnosed predominately in female population, usually between the age group of 20 and 60 years.¹⁶
frequently reported symptom is pain. Cutaneous and soft tissue EHE often present as a painful mass and may cause thrombosis or occlusion in the affected vessel. Although in the present case, the mass was painless and nontender on palpation. In the majority of cases, EHE is multifocal or metastatic at diagnosis.

EHE cases show noticeable nuclear atypia with prominent nucleoli, focal and solid growth patterns, necrotic foci, and higher mitotic activity (> 2 mitoses per 10 HPF) in approximately 10% of cases. These characteristics are valuable diagnostic hints and also suggestive of the aggressive nature of the disease. EHE has numerous morphological features

Fig. 1 Contrast-enhanced computed tomography (CT) (A) and positron emission tomography (PET) images (B) showing soft tissue lesion seen in the right hemimandible causing cortical erosion and involving the submandibular gland inferiorly with an enhancing centrally necrotic left submandibular lymphadenopathy and (C) mild fluorodeoxyglucose (FDG) avid multiple parenchymal nodules were noted in bilateral lung fields suggestive of metastasis.
that are indistinguishable from melanomas, carcinomas, and epithelioid sarcomas but the important differential diagnosis is with primary or metastatic carcinomas. CD31, CD34, ERG, and FLI-1 are endothelial differentiation markers frequently expressed in EHE.\textsuperscript{19,20} Less than 30% of cases showed focal cytokeratin immunopositivity.\textsuperscript{21}

EHE at a molecular level is represented by YAP1-TFE3 (10%) or WWTR1-CAMTA1 (90%) gene fusions.\textsuperscript{22–24} The molecular characterization of EHE is highly recommended for diagnostic confirmation and rule out the differential diagnosis, like angiosarcoma and epithelioid hemangioendothelioma. Unlike EHE with WWTR1-CAMTA1 fusion, EHE with YAP1-TFE3 consist of epithelioid neoplastic cells with bright copious eosinophilic cytoplasm and focally unequivocal vasoformative features.\textsuperscript{23,24} Although, currently molecular study has no predictive or prognostic value, neither can it be utilized for treatment stratification purposes.

Surgical excision with regional nodal resection is the standard treatment for EHE. The main purpose of surgery is to ensure R0 resection, that is, complete resection of the tumor with microscopic negative margins. The expected cure rate in EHE after R0 resection is 70 to 80%.\textsuperscript{25} The risk of recurrence at the local site is approximately 10 to 15% following complete surgical resection.\textsuperscript{10} Although EHE is assumed to be a moderately radiosensitive tumor, the role of adjuvant RT is not well established. Indications of adjuvant RT can be extrapolated from the principles and management of soft tissue sarcomas (STS) of the extremity. Adjuvant RT can be considered in cases of close or positive margin to optimize the treatment outcome. Adjuvant RT is advisable to a dose of 60 Gy in patients with positive or close margins or cases where there is a higher risk of local recurrence. Local irradiation after resection of bone EHE up to 60 Gy showed no locoregional failures on 2 years’ follow-up.\textsuperscript{26} In the present case study, adjuvant RT was planned for the patient as medial and lateral inked margins were positive for tumor cells.

The role of preoperative RT is unclear, as there are no cases published so far for EHE. But for cases where positive or close surgical margins is expected following surgery, preoperative RT to a dose of 50 Gy in 25 fractions may be considered as per standard STS protocols. In cases where the disease is unresectable, definitive RT to a total dose of 60 Gy, 1.8 to 2 Gy/fraction has been recommended. However, depending on the clinical burden, distant metastasis, and symptoms, RT can also be delivered in a palliative setting.\textsuperscript{17} Moreover, in neoadjuvant or adjuvant settings, none of the literature supports the use of systemic therapy in patients with resectable EHE.

Cytotoxic chemotherapy and tyrosine kinase inhibitors are the different options for systemic therapy. Although cytotoxic chemotherapy, such as single-agent gemcitabine, can be considered, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors pazopanib, an

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Fig_2}
\caption{Histopathological findings. (A) Cords of cells infiltrating and destroying bone and embedded in a myxohyaline matrix, hematoxylin and eosin (H&E) stain, 10 \times . (B) Perineural invasion, H&E stain, 10 \times . (C) Partly viable tumor and partly coagulative necrosis (in the upper half of image), H&E stain, 10 \times . (D) Immunohistochemistry for CD34, showing positivity for tumor cells and interspersed vessels within the tumor, DAB-H, 10 \times . H&E, hematoxylin and eosin stain; DAB-H, diaminobenzidine-hematoxylin.}
\end{figure}
antiangiogenic drug in phase III trial of STS, showed successful results.\(^{27}\) Pazopanib resulted in clinical improvement and control of liver and lung metastasis for almost 8 years in a young female with EHE with distant metastases.\(^{28}\) It was well tolerated with no major side effects compared to cytotoxic therapies. Pazopanib therapy was considered postsurgery and radiochemotherapy in the present study to target lung metastasis and reduce the risk of locoregional recurrence.

The efficacy of other targeted agents such as VEGFR inhibitors (bevacizumab, sorafenib), mammalian target of rapamycin (mTOR) inhibitors (sirolimus), and immunomodulatory drugs (lenalidomide) in the treatment of EHE is limited, and further studies are required to determine treatment strategies. However, mTOR inhibitors have been marked with the highest clinical activity, with progression-free survival (PFS) and overall survival of approximately 1 and 2 years, respectively. An even longer PFS has been reported in 10% of patients.\(^{24}\) The systemic approach is preferred treatment option for advanced, metastatic, and progressive EHE. Owing to the rarity of the disease, no standard treatment protocols for EHE exist. To assess clinical outcomes in EHE, a case-by-case treatment approach and follow-up strategies are needed (\(\text{Table } 1\)).

### Table 1: Literature review of epithelioid hemangioendotheliomas in the intraoral region and treatment outcomes

<table>
<thead>
<tr>
<th>No.</th>
<th>Study</th>
<th>Year</th>
<th>No. of cases</th>
<th>Age</th>
<th>Site</th>
<th>Treatment</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Wesley et al(^{29})</td>
<td>1975</td>
<td>1</td>
<td>18</td>
<td>Mandibular gingiva</td>
<td>Surgical excision</td>
<td>NED, 2 years</td>
</tr>
<tr>
<td>2.</td>
<td>Mentzel et al(^{30})</td>
<td>1997</td>
<td>5</td>
<td>30-65</td>
<td>Soft tissue, cheek and neck</td>
<td>Surgical excision</td>
<td>NED, 42–60 months</td>
</tr>
<tr>
<td>3.</td>
<td>Ebo et al(^{31})</td>
<td>1986</td>
<td>1</td>
<td>NA</td>
<td>Gingiva</td>
<td>Surgical excision</td>
<td>NED, 36 months</td>
</tr>
<tr>
<td>4.</td>
<td>Ellis and Kratochvil(^{32})</td>
<td>1986</td>
<td>12</td>
<td>4-67</td>
<td>Neck, gingiva</td>
<td>WLE and surgical excision</td>
<td>LN metastases 2 cases, Recurrence: 1 case</td>
</tr>
<tr>
<td>5.</td>
<td>Moran et al(^{33})</td>
<td>1987</td>
<td>1</td>
<td>25</td>
<td>Palate</td>
<td>Surgical excision</td>
<td>NED, 21 months</td>
</tr>
<tr>
<td>6.</td>
<td>de Araújo et al(^{34})</td>
<td>1987</td>
<td>1</td>
<td>4</td>
<td>Gingiva</td>
<td>Surgical excision</td>
<td>NA</td>
</tr>
<tr>
<td>7.</td>
<td>Marrogi et al(^{3})</td>
<td>1991</td>
<td>2</td>
<td>36-45</td>
<td>Tongue, gingiva</td>
<td>Surgical excision</td>
<td>Recurrence: 1 case</td>
</tr>
<tr>
<td>8.</td>
<td>Flaitz et al(^{35})</td>
<td>1995</td>
<td>1</td>
<td>7</td>
<td>Gingiva</td>
<td>WLE</td>
<td>NED, 48 months</td>
</tr>
<tr>
<td>9.</td>
<td>Kiryu et al(^{36})</td>
<td>1996</td>
<td>1</td>
<td>46</td>
<td>Soft tissue, cheek</td>
<td>Surgical excision</td>
<td>NED, 36 months</td>
</tr>
<tr>
<td>10.</td>
<td>Orsini et al(^{37})</td>
<td>2001</td>
<td>1</td>
<td>18</td>
<td>Buccal mucosa</td>
<td>Surgical excision</td>
<td>Recurrence: 9 months</td>
</tr>
<tr>
<td>11.</td>
<td>Chi et al(^{38})</td>
<td>2005</td>
<td>1</td>
<td>28</td>
<td>Gingiva</td>
<td>Surgical excision</td>
<td>NED, 8 months</td>
</tr>
<tr>
<td>12.</td>
<td>Rigby et al(^{39})</td>
<td>2006</td>
<td>1</td>
<td>34</td>
<td>Soft tissue, neck</td>
<td>Surgical excision</td>
<td>NED, 84 months</td>
</tr>
<tr>
<td>13.</td>
<td>Yoruk et al(^{40})</td>
<td>2008</td>
<td>1</td>
<td>44</td>
<td>Submandibular region</td>
<td>Surgical excision</td>
<td>NED, 6 months</td>
</tr>
<tr>
<td>14.</td>
<td>Sun et al(^{41})</td>
<td>2007</td>
<td>9</td>
<td>6-53</td>
<td>Tongue ((n = 4),) lip ((n = 1)), gingiva and alveoli of the maxilla/mandible ((n = 2),) buccal mucosa ((n = 1),) FOM ((n = 1)).</td>
<td>Surgical excision</td>
<td>NED, 6 months–8 years, Recurrence in 3 cases</td>
</tr>
<tr>
<td>15.</td>
<td>Mohtasham et al(^{42})</td>
<td>2008</td>
<td>1</td>
<td>9</td>
<td>Maxillary gingiva</td>
<td>Surgical excision</td>
<td>Recurrence, 1-year</td>
</tr>
<tr>
<td>16.</td>
<td>Gordón-Núñez et al(^{43})</td>
<td>2010</td>
<td>1</td>
<td>17</td>
<td>Mandibular gingiva</td>
<td>Surgical excision</td>
<td>NED, 21 months</td>
</tr>
<tr>
<td>17.</td>
<td>Salgarelli et al(^{4})</td>
<td>2016</td>
<td>1</td>
<td>32</td>
<td>Mandibular gingiva</td>
<td>Surgical excision</td>
<td>Node metastases after 4 years</td>
</tr>
<tr>
<td>18.</td>
<td>Ranjit et al(^{44})</td>
<td>2015</td>
<td>1</td>
<td>25</td>
<td>Submandibular region</td>
<td>Surgical excision</td>
<td>NA</td>
</tr>
<tr>
<td>19.</td>
<td>Present case</td>
<td>2021</td>
<td>1</td>
<td>56</td>
<td>Mandible and submandibular region with lung metastasis</td>
<td>Surgical excision → chemotherapy → pazopanib</td>
<td>On follow-up disease free</td>
</tr>
</tbody>
</table>

Abbreviations: FOM, floor of mouth; LN, lymph node; NA, not available; NED, no evidence of disease; WLE, wide local excision.

Conclusion

EHE is a rare tumor with a borderline behavior between hemangiomas and malignant angiosarcomas. The surgical excision of tumor is the standard approach for localized disease and adjuvant RT use can be extrapolated from the management of STS guidelines. Considering its aggressive behavior and high propensity for distant metastasis and with
no standard treatment guidelines, an individual case-based multimodality approach should be considered to get the best treatment outcomes.

Ethics Approval and Consent to Participate
For submission of a case report, clearance from the Institute Ethics Committee is waived at All India Institute of Medical Sciences, Jodhpur. It is notable that the patient was not subjected to any experimental investigation or treatment at any point of time.

Consent for Publication
Written informed consent was obtained from the patient’s guardian for publication of this case report and accompanying images.

Availability of Data and Materials
All data generated or analyzed during this study are included in this published article.

Competing Interests
The authors declare that they have no competing interests.

Authors’ Contributions
S.S., B.D.: Conception and design of this study, acquisition of data, analysis and interpretation of data, and drafting. All authors read and approved the final manuscript.

Patient Consent

Funding
None.

Conflict of Interest
None declared.

Acknowledgments
None.

References